Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics

Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular eve...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Transl Med
Main Authors: Bovijn, Jonas, Krebs, Kristi, Chen, Chia-Yen, Boxall, Ruth, Censin, Jenny C., Ferreira, Teresa, Pulit, Sara L., Glastonbury, Craig A., Laber, Samantha, Millwood, Iona Y., Lin, Kuang, Li, Liming, Chen, Zhengming, Milani, Lili, Smith, George Davey, Walters, Robin G., Mägi, Reedik, Neale, Benjamin M., Lindgren, Cecilia M., Holmes, Michael V.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116615/
https://ncbi.nlm.nih.gov/pubmed/32581134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aay6570
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados